Novartis-GSK asset swap offers template for pharma and beyond
* Scope for deals in consumer goods sector * Asset swaps avoid merger pitfalls By Ben Hirschler, Martinne Geller and Anjuli Davies LONDON, April 23 (Reuters) - The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion
Read more